TuHURA BIOSCIENCES, INC./NV Net Cash Provided by (Used in) Financing Activities, Continuing Operations
TuHURA BIOSCIENCES, INC./NV (HURA) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $8.94 million for the 6-month period ending 2017-12-31, per its 10-Q filed 2018-02-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2018-02-14
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-12-31 was -$2.09K, a 103.09% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-09-30 was $8.94M, a 3409.21% increase year-over-year.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-12-31 was $67.67K.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-09-30 was $254.85K.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $8.47M, a 11.46% decline from fiscal 2016.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $9.57M.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for fiscal 2013 was $9.64M, a 1559.70% increase from fiscal 2012.
- TuHURA BIOSCIENCES, INC./NV net cash provided by (used in) financing activities, continuing operations for fiscal 2012 was $580.80K, a 164.80% increase from fiscal 2011.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 14 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 36 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 42 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 45 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 48 month |
|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$2.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-14 | $8.94M 10-Q · filed 2018-02-14 | |||||||
| 2017-09-30 | $8.94M 10-Q · filed 2017-11-09 | ||||||||
| 2017-06-30 | $8.47M 10-K · filed 2017-09-27 | ||||||||
| 2016-12-31 | $67.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-14 | $322.52K 10-Q · filed 2018-02-14 | |||||||
| 2016-09-30 | $254.85K 10-Q · filed 2017-11-09 | ||||||||
| 2016-06-30 | $9.57M 10-K · filed 2017-09-27 | ||||||||
| 2015-03-31 | $27.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $763.81K derived: sum of 2 quarters · filed 2015-05-15 | $1.29M 10-Q · filed 2015-05-15 | $3.55M derived: sum of 4 quarters · filed 2015-05-15 | |||||
| 2014-12-31 | $736.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-12 | $1.26M 10-Q · filed 2015-02-12 | $3.52M derived: sum of 3 quarters · filed 2015-02-12 | $3.74M derived: sum of 4 quarters · filed 2015-02-12 | |||||
| 2014-09-30 | $527.55K 10-Q · filed 2014-11-07 | $2.79M derived: sum of 2 quarters · filed 2014-11-07 | $3.01M derived: sum of 3 quarters · filed 2014-11-07 | $3.01M derived: sum of 4 quarters · filed 2014-11-07 | |||||
| 2014-06-30 | $2.26M derived: 10-K 6 month − 10-Q 3 month · filed 2014-08-28 | $2.48M 10-K · filed 2014-08-28 | $2.48M derived: sum of 3 quarters · filed 2014-08-28 | $2.48M derived: sum of 4 quarters · filed 2014-08-28 | |||||
| 2014-03-31 | $221.85K 10-Q · filed 2014-05-15 | $221.85K derived: sum of 2 quarters · filed 2014-08-28 | $221.85K 10-Q · filed 2015-05-15 | $221.85K derived: sum of 4 quarters · filed 2014-08-28 | $10.83M 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-28 | $0.00 derived: sum of 2 quarters · filed 2014-08-28 | $0.00 derived: sum of 3 quarters · filed 2014-08-28 | $9.64M 10-K · filed 2014-08-28 | $10.60M 10-K · filed 2014-03-10 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-K 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2014-08-28 | $9.64M 10-Q · filed 2013-11-08 | $9.55M derived: sum of 4 quarters · filed 2014-08-28 | $10.60M 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2014-08-28 | $9.64M 10-K · filed 2014-08-28 | $9.55M derived: sum of 3 quarters · filed 2014-08-28 | $9.55M derived: sum of 4 quarters · filed 2014-08-28 | $10.60M 10-Q · filed 2013-08-12 | ||||
| 2013-03-31 | $9.64M 10-Q · filed 2014-05-15 | $9.55M derived: sum of 2 quarters · filed 2014-08-28 | $9.55M derived: sum of 3 quarters · filed 2014-08-28 | $8.11M derived: sum of 4 quarters · filed 2014-08-28 | $10.60M 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | -$90.77K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-28 | -$90.77K derived: sum of 2 quarters · filed 2014-08-28 | -$1.53M derived: sum of 3 quarters · filed 2014-08-28 | $580.80K 10-K · filed 2014-08-28 | |||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$1.44M derived: sum of 2 quarters · filed 2013-11-08 | $671.57K 10-Q · filed 2013-11-08 | ||||||
| 2012-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $671.57K 10-Q · filed 2013-08-12 | |||||||
| 2012-03-31 | $2.11M 10-Q · filed 2013-05-15 | ||||||||
| 2011-12-31 | $219.33K 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |